Green light in France for Sensorion’s clinical trial of its latest gene therapy treatment

The Montpellier-based biotechnology company, Sensorion, has bounced back after abandoning SENS-501, announcing that it has obtained approval to conduct clinical trials in France for SENS-601. This is an experimental gene therapy for the treatment of hearing loss linked to the GJB2 gene, which accounts for 22.2% of cases of hearing loss, according to a study published in Genetics in Medicine ....

Continue reading at Audiology Worldnews →

No actionable change — this is an early-stage regulatory clearance to begin clinical trials; no efficacy or safety data in humans is yet available for SENS-601.

Regulatory clearance for a GJB-targeted gene therapy trial marks a meaningful step toward a potential disease-modifying treatment for one of the most prevalent forms of genetic hearing loss, keeping the audiology field's attention on gene therapy as a future care pathway.

1. 01French regulators have approved Sensorion to begin human clinical trials for SENS-601 gene therapy.
2. 02SENS-601 targets hearing loss caused by mutations in the GJB gene family, a common genetic cause of hearing impairment.
3. 03This follows Sensorion's earlier decision to discontinue its SENS-501 program, representing a strategic pivot.
4. 04No human efficacy or safety data for SENS-601 has been published yet.
5. 05The trial approval signals growing regulatory openness to gene therapy approaches in audiology.

Publication type

clinical_trial

Evidence level

na

Population

Individuals with hearing loss associated with GJB gene mutations

Intervention

SENS-601 gene therapy targeting GJB gene mutations